SG10201610913PA - Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations - Google Patents

Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Info

Publication number
SG10201610913PA
SG10201610913PA SG10201610913PA SG10201610913PA SG10201610913PA SG 10201610913P A SG10201610913P A SG 10201610913PA SG 10201610913P A SG10201610913P A SG 10201610913PA SG 10201610913P A SG10201610913P A SG 10201610913PA SG 10201610913P A SG10201610913P A SG 10201610913PA
Authority
SG
Singapore
Prior art keywords
alpha1
delaying
onset
progression
proteinase inhibitor
Prior art date
Application number
SG10201610913PA
Other languages
English (en)
Inventor
Mark Forshag
Royce Waltrip
Les Garlinghouse
William Barnett
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of SG10201610913PA publication Critical patent/SG10201610913PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/002Details of inhalators; Constructional features thereof with air flow regulating means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0018Details of inhalators; Constructional features thereof with exhalation check valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0085Inhalators using ultrasonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG10201610913PA 2011-12-30 2012-11-22 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations SG10201610913PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161581708P 2011-12-30 2011-12-30

Publications (1)

Publication Number Publication Date
SG10201610913PA true SG10201610913PA (en) 2017-02-27

Family

ID=47470050

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201610913PA SG10201610913PA (en) 2011-12-30 2012-11-22 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations
SG2014012066A SG2014012066A (en) 2011-12-30 2012-11-22 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2014012066A SG2014012066A (en) 2011-12-30 2012-11-22 Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Country Status (19)

Country Link
US (1) US9421248B2 (es)
EP (1) EP2758065B1 (es)
JP (4) JP2015504051A (es)
KR (1) KR20140108516A (es)
CN (2) CN103889436A (es)
AR (2) AR088971A1 (es)
AU (1) AU2012337241B2 (es)
BR (1) BR112014007127A2 (es)
CA (1) CA2844878C (es)
CL (1) CL2014000722A1 (es)
ES (1) ES2887358T3 (es)
HK (1) HK1198918A1 (es)
IL (1) IL231109B (es)
MX (1) MX351189B (es)
MY (1) MY166314A (es)
RU (1) RU2635482C2 (es)
SG (2) SG10201610913PA (es)
UY (1) UY34465A (es)
WO (1) WO2013098672A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015018840A2 (en) * 2013-08-05 2015-02-12 Gerard Voerman Novel means to decrease the negative effects of smoking
JP6783767B2 (ja) * 2014-12-22 2020-11-11 アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. 組換えタンパク質を精製する方法
FI3253406T3 (fi) * 2015-02-05 2024-01-18 Canem Holdings Llc Koostumukset granulomatoottisen polyangiitin hoitamista varten
IL268752B2 (en) * 2017-02-21 2024-01-01 Kamada Ltd Methods and uses of alpha 1-antitrypsin for early intervention in lung diseases
US10663434B2 (en) * 2017-03-31 2020-05-26 Sonix, Inc. Wafer chuck
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
AU2021263106A1 (en) * 2020-05-01 2022-11-03 Ageronix SA Treatment and/or prevention of a disease or a syndrome related to a virus infection

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE395611B (sv) 1975-12-12 1977-08-22 Draco Ab Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser
SE411705B (sv) 1976-11-09 1980-02-04 Draco Ab Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4667688A (en) 1983-11-28 1987-05-26 Francisco Roig Mini pack of cigarettes
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下1▼−アンチトリプシン誘導体及びその製造法
US4697003A (en) 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US6231851B1 (en) 1994-05-18 2001-05-15 Inhale Therapeutic Systems Methods and compositions for the dry powder formulation of interferons
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
DK0748213T3 (da) 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
EP0871671A1 (en) 1995-09-07 1998-10-21 PPL Therapeutics (Scotland) Limited Purification of alpha-1 proteinase inhibitor
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
EE200000546A (et) 1998-03-16 2002-02-15 Inhale Therapeutic Systems, Inc. Aerosoolistatud toimeaine manustamissüsteem
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
CA2430973A1 (en) 2000-12-18 2002-06-27 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP1664123B2 (en) 2003-09-22 2011-11-30 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
EP1684719B1 (en) 2003-11-14 2011-10-26 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
WO2007091266A2 (en) * 2006-02-09 2007-08-16 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
WO2010009388A1 (en) * 2008-07-18 2010-01-21 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
HUE039240T2 (hu) * 2009-11-03 2018-12-28 Grifols Therapeutics Llc Kompozíció, eljárás és készlet alfa-1 proteináz inhibitorhoz

Also Published As

Publication number Publication date
CA2844878C (en) 2017-11-28
JP2018104439A (ja) 2018-07-05
CN107596359A (zh) 2018-01-19
WO2013098672A2 (en) 2013-07-04
CL2014000722A1 (es) 2014-10-10
AR088971A1 (es) 2014-07-23
IL231109B (en) 2018-02-28
EP2758065A2 (en) 2014-07-30
US20150011460A1 (en) 2015-01-08
MX351189B (es) 2017-10-04
AR116887A2 (es) 2021-06-23
WO2013098672A3 (en) 2013-10-24
RU2635482C2 (ru) 2017-11-13
NZ621596A (en) 2016-08-26
CA2844878A1 (en) 2013-07-04
ES2887358T3 (es) 2021-12-22
IL231109A0 (en) 2014-04-30
MX2014001764A (es) 2014-04-30
MY166314A (en) 2018-06-25
US9421248B2 (en) 2016-08-23
KR20140108516A (ko) 2014-09-11
JP2015504051A (ja) 2015-02-05
CN103889436A (zh) 2014-06-25
JP2017039745A (ja) 2017-02-23
AU2012337241B2 (en) 2016-10-13
BR112014007127A2 (pt) 2017-04-04
UY34465A (es) 2013-07-31
AU2012337241A1 (en) 2013-07-18
SG2014012066A (en) 2014-09-26
RU2014106758A (ru) 2015-08-27
EP2758065B1 (en) 2021-06-23
HK1198918A1 (en) 2015-06-19
JP2019135243A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
HK1199203A1 (en) Kinase inhibitor polymorphs
HK1200828A1 (en) Kinase inhibitors
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
HUE048834T2 (hu) Kináz inhibitorok
HK1198918A1 (en) Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations 1-
EP2766723A4 (en) MULTIPLEXED KINASE INHIBITOR BALLS AND USES THEREOF
EP2680844A4 (en) AMINOCHINOLINE AS A KINASEHEMMER
EP2827849A4 (en) TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN
IL229028A0 (en) Kinase inhibitors
HK1199873A1 (en) Kinase inhibitors
HK1201271A1 (en) Kinase inhibitor polymorphs
GB2499487B (en) Floating-point of the invention
GB2510524B (en) Pulmonary hypertension
SG10201507170RA (en) Radical inhibitor
EP2758744A4 (en) ANGLE DETERMINATION OF IMPACT
GB201118359D0 (en) Pulmonary hypertension
GB201109162D0 (en) Casein kinase 1Delta (CK1Delta) inhibitors
PL120341U1 (pl) Zespól do powierzchniowej obróbki wlewków aluminium